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Background: The protein kinase C (PKC) family of 
serine/threonine-specific protein kinases is involved in 
many cellular processes, and the-unregulated activation of 
PKC has been implicated in carcinogenesis. PKC 
inhibitors thus have significant potential as chemothera- 
peutic agents. Recently, the fungal metabolite balanol 
was shown to be an exceptionally potent inhibitor of 
PKC. We previously developed a practical and efficient 
total synthesis of balanol. We set out to use this synthetic 
molecule, and several synthetic analogs, to probe the 
mechanism of PKC inhibition and to determine the 
effect of balanol on the activity of other protein kinases. 
Results: As well as inhibiting PKC, balanol is a potent 
inhibitor of cyclic AMP-dependent protein kinase 
(P&4), another protein serine/threonine kinase. Balanol 
does not, however, inhibit the Src or epidermal growth 
factor receptor protein tyrosine kinases. The inhibition of 
both PKC and PKA by balanol can be overcome by high 
concentrations of ATP, and molecular modeling studies 
suggest that balanol may function as an ATP structural 
analog. Although balanol discriminates rather poorly 
between PKC and PKA, only minor modifications to its 
molecular structure are required to furnish compounds 
that are highly specific inhibitors of PKA. 
Conclusions: A number of balanol analogs have been 
designed and synthesized that, unlike balanol itself, 
exhibit dramatic selectivity between PKA and PKC. 
Thus, despite the substantial homology between the 
catalytic domains of PKA and PKC, there is enough dif- 
ference to allow for the development of potent and selec- 
tive inhibitors acting in this region. These inhibitors 
should be useful tools for analyzing signal transduction 
pathways and may also aid in the development of drugs 
with significant therapeutic potential. 
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Introduction 
The protein kinase C (PKC) family of enzymes [l-7] cat- 
alyzes the transfer of the y-phosphate from adenosine 
triphosphate (ATP) to serine or threonine residues on 
their substrate proteins. PKC-mediated phosphorylation is 
important in the regulation of a variety of cellular 
processes, including gene expression and cell proliferation, 
and the unregulated activation of PKC has been impli- 
cated in a number of disease states including carcinogene- 
sis [8]. Intensive efforts have thus been made over the last 
few years to identify potent and selective inhibitors of 
PKC. The compound balanol (compound 1, Fig. l), a 
metabolic product of the fungus !&icillium balanoides, was 
recently isolated and found to inhibit PKC in low 
nanomolar concentrations [9,10]. The recent chemical 
synthesis of balanol by ourselves [l l] and others ([12] and 
N.Vicker, personal communication) presented us with an 
opportunity to probe the mechanism of PKC inhibition 
and to investigate whether balanol could inhibit other 
protein kinases. Furthermore, through modification of our 
synthetic strategy, we wished to prepare structurally more 
simple variants of the natural product [13], with the dual 
aims of delineating the functional requirements for PKC 
inhibition and developing novel balanoids with superior 
activity and selectivity profiles. 
Results and discussion 
Biological activity of balanol 
Synthetic balanol, which was identical to the natural 
product in all respects [l 1,131, was used in our biological 
assays. Balanol was found to be a potent inhibitor of 
purified rat brain protein kinase C (PKC), with an IC,, 
of 4 nM (Fig. 2a). To determine whether balanol inter- 
acted at a known cofactor- or substrate-binding site on 
PKC, inhibition by balanol was examined in the pres- 
ence of varying concentrations of histone, diolein, phos- 
phatidylserine or ATp Thus, the substrate or cofactor 
concentration was varied over a broad range and PKC 
activity was assessed in the absence or presence of 10 nM 
balanol. For histone, diolein and phosphatidylserine the 
effect of balanol was non-competitive, that is, the 
inhibitory effect of balanol was observed over the entire 
concentration range of the variable and was not sur- 
mounted by increasing the concentration of the variable 
component. Only ATP acted competitively with balanol, 
with high concentrations overcoming the inhibitory 
effect of balanol to achieve maximal enzyme activity 
(Fig. 2e). These data are consistent with the findings of 
Ohshima et al. [lo] and suggest that balanol and ATP 
compete for binding to the same site in the catalytic 
domain of PKC. 
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Fig. 1. Molecular structure of balanol (compound 1). 
Balanol also inhibited the activity of the catalytic (C) 
subunit of the cyclic AMP-dependent protein kinase 
(PKA) ]14-211, with an IC,, of 4 nM (Fig. 3a), identical 
to that for inhibition of PKC. The competition profiles 
were similar to those for PKC. Increasing concentrations 
of phosphate acceptor did not overcome the effect of 
balanol (Fig. 3b), h w ereas ATP at sufficiently high concen- 
trations did (Fig. 3c), implying that balanol was acting 
competitively with ATP Results obtained with the puri- 
fied recombinant C subunit of PKA (cPKA) and with the 
holoenzyme (purified from rabbit muscle) assayed in the 
presence of CAMP were similar. 
The effectiveness of balanol as an inhibitor of PKA and 
PKC, both protein serine/threonine kinases, raised the 
question of specificity of balanol toward protein kinases 
in general. We tested balanol against two protein tyro- 
sine kinases, the epidermal growth factor receptor 
(EGFR) kinase and the Src kinase (pp60 Src). Balanol 
did not inhibit either of these protein kinase activities, 
whereas known inhibitors were effective (Fig. 4). Tested 
against this small number of protein kinases, balanol 
seems effective against protein serine/threonine kinases 
and ineffective against protein tyrosine kinases. The 
effect of balanol on a broader range of protein kinases is 
currently under investigation. 
Molecular modeling studies for balanol 
To gain further insight into the action of balanol, and to 
aid our design of novel balanoids, we generated a struc- 
tural model of the inhibitor through a combination of 
conformational analysis (using Monte Carlo methods) 
and ab initio calculations. An initial conformation for 
balanol (neutral non-zwitterionic form) was constructed 
using the program MacromodelV3.5X and energy mini- 
mized in the MM2 force field (500 steps of energy mini- 
mization using a conjugate gradient algorithm). A Monte 
Carlo conformational search was then performed using a 
water solvation model [22], allowing complete freedom 
of movement for all the rotatable bonds to search for the 
global minimum energy conformation. This conforma- 
tion was then optimized using the PM3 program con- 
tained in the MOPAC software package (128 steps of 
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Fig. 2. Inhibition of PKC by balanol can be overcome by high concentrations of ATP. (a) Effect of balanol and staurosporine on PKC 
activity. (b)-(e) PKC activity assayed in the absence (open circles) or presence (solid circles) of 10 nM balanol as a function of the 
concentration of (b) peptide substrate, (c) diolein, (d) phosphatidylserine (PS), or (e) ATP. The apparent K, for ATP is 16 p,M in this 
experiment and 26 f 12 FM in the aggregate (mean + standard error measurement (SEM) of three independent determinations). 
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Fig. 3. Balanol inhibits the activity of 
cyclic AMP-dependent protein kinase 
(PKA). (a) Effect of balanol and stauro- 
sporine on PKA activity. (b) & (c) PKA 
activity assayed in the absence (open 
circles) and presence (solid circles) of 
10 nM balanol as a function of the 
concentration of (b) substrate (histone) 
or (c) ATP. The apparent K, for ATP 
is IO FM in this experiment and 
16 + 7 PM in the aggregate (mean + SEM 
of four independent determinations). 
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geometry optimization until the self-consistent field 
(SCF) gradient was < 0.01) to afford the final balanol 
model (heat of formation = -325.99 kcal mol-I). The 
conformation of the central hexahydroazepine ring and 
the orientation of the benzoyl amide fragment obtained 
in these modeling studies were completely consistent 
with the experimental data currently available from lH 
NMR experiments [9]. Furthermore, because of the 
limited conformational flexibility available to balanol, it is 
reasonable to suggest that this structural model for balanol 
(Fig. 5) approximates the conformation involved in 
protein kinase inhibition. 
The active sites of all eukaryotic protein kinases have a 
high degree of homology [23] and there is increasing 
evidence for a common mechanism of catalysis for phos- 
phoryl transfer [19].The structure of the catalytic subunit 
of PKA (cPKA) has been determined crystallographically 
[l&21] and may serve as an excellent model for the cat- 
alytic domains of other protein serine/threonine kinases 
such as PKC [24]. We hypothesized that the potent 
inhibitory properties of balanol might stem from its 
ability to serve as a structural analog ofATP.The confor- 
mation ofATP found in the crystal structure [16,17] of 
the ternary complex between cPKA, MnATP and a 
pseudosubstrate peptide corresponding to residues 5-24 
of the naturally occurring, heat-stable protein kinase 
inhibitor (PKI) was compared to that of our balanol 
model. There is striking similarity in the overall shape 
and size of the two molecules (Fig. 5). In addition, the 
oxygen-rich benzophenone domain of balanol closely 
correlated with the triphosphate moiety ofATP, and the 
hydrophobic benzoyl amide fragment correlated with 
the adenine region. In the structural model of balanol, 
the central hexahydroazepine ring projects these two key 
domains in an orientation that is close to that of the cor- 
responding groups in cPKA-bound ATP The implication 
that balanol could to some extent mimic ATP was sup- 
ported by a docking experiment using our structural 
model of balanol and the ATP-binding region of the 
cPKA active site (INSIGHT II, v.2.3 software package). 
This experiment suggested that balanol could fit com- 
fortably in the cleft between the small and large lobes of 
the catalytic subunit, with the benzoyl amide domain 
embedded in the hydrophobic pocket. It is important to 
note that this inhibitor-protein complex did not appear 
to suffer from any prohibitive van der Waals clashes. 
Molecular design of novel balanol analogs 
We prepared a number of designed analogs of balanol 
(Fig. 6) to probe the importance of particular functional 
groups for inhibitory activity. The syntheses of the 
designed analogs were carried out by appropriate modi- 
fication of our chemical synthesis for balanol and are 
described elsewhere [13]. 
The benzophenone fragment 2 and hexahydroazepine 
fragment 3 represent the two halves of the balanol 
molecule. These analogs were prepared [13] to assess 
whether the presence of both major domains of balanol 
is required for activity. The observation that both com- 
pounds were ineffective inhibitors (IC,, > 10e6 M) 
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Fig. 4. Balanol does not inhibit protein tyrosine kinases. 
Activity of (a) EGFR kinase domain or (b) Src kinase in the 
presence of various concentrations of balanol. The open circle 
shows the effect of equivalent diluent (30 % DMSO) for the 
highest concentration of balanol used. 
against PKA (Fig. 7a) suggested that the complete 
balanol backbone should be retained for inhibitory 
activity. The molecular modeling analysis described 
above demonstrated that the oxygen-rich benzophe- 
none fragment of balanol could correspond to the 
triphosphate region of ATP To examine the importance 
of this region, the analogs lo”-deoxybalanol (4), 14”- 
decarboxybalanol (5), and 4”,6”-dideoxybalanol (6) 
were prepared [13]. The binding of the adenine frag- 
ment ofATP in the hydrophobic pocket of the cPKA 
catalytic domain may be stabilized through the forma- 
tion of a hydrogen bond with the amino moiety [19]. 
The docking of balanol and cPKA showed that the 
p-hydroxybenzoyl amide fragment may be embedded 
in this hydrophobic pocket, and the implication that 
a hydrogen bond with the 5’-hydroxyl moiety of 
balanol might be important for binding was tested 
using the 5’-deoxybalanol analog (compound 7). 
Biological evaluation of balanol analogs (4-7) 
The inhibitory activities of balanol and its analogs 4-7 
against PKC and cPKA are shown in Figure 7 and com- 
pared in Table 1. Although all of the designed analogs 
suffered a significant loss of activity for PKC inhibition, a 
number of them were still potent inhibitors of cPKA. 
For example, although the decarboxy analog 5 was a 
poor inhibitor of PKC (IC,, = 5 FM), it did not suffer a 
substantial decrease in potency for inhibition of cPKA 
vc50 = 18 nM). Analogs 6 and 7 both inhibited cPKA 
with IC,, values similar to that of balanol (5.5 nM and 
5.7 nM, respectively) but were significantly less active as 
PKC inhibitors (IC,, = 111 nM and 95 nM, respec- 
tively). The high potency of the decarboxylated analog 
(7) for inhibition of cPKA suggests that a hydrogen- 
bonding interaction with the hydrophobic portion of 
balanol is not essential for binding. The lo”-deoxy- 
balanol analog (4) and the 14”-decarboxybalanol analog 
(5) exhibited the most dramatic selectivity for cPKA. 
These analogs were found to be approximately as potent 
as balanol for the inhibition of cPKA (IC,, = 6.3 nM 
and 18 nM, respectively) but were 125-fold to lOOO-fold 
less effective than balanol against PKC (IC,, = 834 nM 
and 6.9 PM, respectively). It is important to note that the 
inhibition of cPKA by lo”-deoxybalanol (4) also could 
be overcome by high concentrations of ATP (data not 
shown), thus confirming that these new balanoids were 
also acting at the ATP-binding site. 
The observation that such minor structural alterations can 
lead to a marked differentiation in protein kinase selectiv- 
ity suggests that the binding of balanol at the catalytic 
Fig. 5. Comparison of the molecular structures of balanol (above) 
and the bound conformation of ATP in cPKA (below). Atom 
colors: carbon, black; hydrogen, white; oxygen, red; nitrogen, 
blue; phosphorus, yellow. Hydroxyl hydrogen atoms on balanol 
have been omitted for clarity. 
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Fig. 6. Molecular structures of designed 
balanol analogs. 
H6 Hd I 
OMe 
H -OH 
2: Benzophenone 
fragment 
3: Hexahydroazepine 
fragment 
HO& 0 OH OH 0 OH 
q. &f-&O 
OH 
4: 1 O”-Deoxybalanol 5 : 14”-Decarboxybalanol 
hydrochloride 
H02C 0 H02C 0 OH 
q. m. 
6: 4”,6”-Dideoxybalanol 7: 5’-Deoxybalanol 
domains of these kinases is more complex than a straight- 
forward mimicking ofATP.These studies also show that, 
despite the high d egree of similarity between the PKA 
and PKC catalytic domains, they are sufficiently different 
to allow the development of potent and selective 
inhibitors which act in the ATP-binding region. The 
identification of analogs 4 and 5 as selective inhibitors was 
also of practical interest since their chemical syntheses 
were much more straightforward than that of balanol 
itself [13]. To put the above results into perspective, we 
compared the activity of analogs 4 and 5 to that of the 
often-used inhibitor of PKC, staurosporine (compound 8, 
Fig. 8). Consistent with previous reports [25], stauro- 
sporine was not selective for inhibition of PKC over 
cPKA and was considerably less potent toward cPKA 
than either analog or balanol itself (see Table 1). We also 
compared the inhibitory activity of analogs 4 and 5 
with published Ki values for KT5720 (compound 9, Fig. 
8) [26] and H-89 (compound 10, Fig. 8) [27], two of 
the most selective non-peptidic inhibitors of PKA 
reported to date.The novel balanoids 4 and 5 were sig- 
nificantly more potent than these inhibitors against PKA 
Table 1. Inhibition constants for balanol derivatives and staurosporinea. 
Compoundb 
Kinase Balanol (2) (3) (4) (5) (6) (7) Staurosporine 
PKA 4.7 * 1.3 >I03 >I03 3.9 11 3.4 3.5 35 
PKC 5.3 & 1.8 >I 0s >I 0s 640 5000 80 69 19 
aKj values are shown in nM. 
b5ee Figure 6 for the names and structures of compounds 2-7. 
I I 
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Fig. 7. Comparative effects of balanol analogs on PKC and PKA. 
The symbols indicate the different analogs (structures are shown 
in Figs 1 and 6): balanol (I), 0; benzophenone fragment (2), +; 
hexahydroazepine fragment (3), 0 ; 1 O”-deoxybalanol (4), 0 ; 
14”-decarboxybalanol (5), n ; 4”,6”-dideoxybalanol (6), 0; 
S’-deoxybalanol (7), 0. 
and exhibited similar levels of selectivity for PKA com- 
pared to PKC (compound 9, Ki = 56 nM for PKA; 
Ki > 2000 nM for PKC [26]; compound 10, Ki = 48 nM 
for PKA, $ = 31.7 p,M for PKC [27]). 
Significance 
The modulation of protein activity through phos- 
phorylation by protein kinases is fundamental to 
the control of many different cellular events. In 
particular, the signal transduction pathways that 
are regulated by PKC and PKA are now highly 
delineated and it is clear that selective inhibitors of 
these enzymes could prove therapeutically useful. 
PKC and PKA are both serine/threonine-specific 
protein kinases and have a high degree of homol- 
ogy in their catalytic domains. This homology is 
presumably reflected in the observation that 
inhibitors acting at the catalytic domains of these 
enzymes are generally non-selective (e.g. stau- 
rosporine). High enzyme selectivity is, however, 
essential for any inhibitor to be of value either as 
a tool for signal transduction research or as a 
potential drug candidate. 
We have shown that the fungal metabolite balanol, 
originally reported as a PKC inhibitor, also inhibits 
PKA. Nevertheless, based on molecular modeling 
studies, a number of new analogs of balanol have 
been designed and synthesized that show signifi- 
cant selectivity for the inhibition of PKA over 
PKC. In particular, lo”- deoxybalanol (compound 
4) and 14”-decarboxybalanol (compound 5) are 
remarkably potent and selective inhibitors of PKA. 
Thus, although the catalytic domains of PKA and 
PKC show a high degree of homology and prob- 
ably share a common mechanism for phosphoryl 
transfer, they are sufficiently different to allow the 
development of potent and selective inhibitors that 
act at the ATP-binding region. 
Materials and methods 
Materials 
All of the analogs described here were prepared by chemical 
synthesis, as described elsewhere [13]. 
Effects of balanol on activity of PKC 
The activity of PKC was assessed by the addition of 10 to 20 ng 
of purified rat brain PKC (Calbiochem #539494) to a reaction 
mixture (final volume, 100 ~1) consisting of: 10 FM ATP, 
-0.1 p,Ci Y[~~P]ATE 5 mM MgCl,, 0.5 mM CaClz, 50 mM Na+ 
HEPES, pH 7.5, 100 pg ml-’ phosphatidylserine, 3.3 pg ml-’ 
diolein, and either 1 mg ml-l histone Hl or 300 p,M peptide 
substrate (Lys-Arg-Thr-Leu-g-Arg; LC Labs #P-3310). 
8: Staurosporine 
Me(CH2)s@C” 
9: KT5720 
S02NH(CH&NHCH2CH=CH 
--cl- 
/ \ Br 
- 
10: H-89 
Fig. 8. Structures of staurosporine (compound 8), KT5720 
(compound 9) and H-89 (compound IO). 
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Balanol, its derivatives or diluent were included in these reactions 
and were added as 10x working stocks diluted with water from 
stocks made in dimethylsulfoxide (DMSO). DMSO was included 
as a control and was inactive. Reactions were incubated at 30 “C 
for 8 min, then 80 ~1 aliquots were spotted onto phospho- 
cellulose paper (Whatman ~81). Papers were washed extensively 
in 75 mM phosphoric acid and their 32P content determined 
by liquid scintillation spectrometry. Each experimental con& 
tion was duplicated within each assay Data presented are the 
mean + SEM of two to four experiments. 
Effects of balanol on activity of PKA 
The activity of PKA was assessed by the addition of 1 to 20 ng 
of purified recombinant PKA [28] to a reaction mixture (final 
volume, 100 p,l) consisting of! 10 p,M ATP, -0.1 pCi Y[~~P]ATP, 
5 mM MgCl,, 1 n&l DTT, 1 mg ml-’ histone Hf2b and 50 mM 
Na+ HEPES, pH 7.5. Reactions were performed and quantified 
as described above. Data presented are the mean ? SEM of two 
to four experiments. 
Assay of inhibition of protein tyrosine kinases 
The activity of the recombinant EGFR kinase domain [29] (gift 
of Dr Gordon Gill, UC San Diego) was assayed as described 
[29] using angiotensin II (2 mM) as the phosphate acceptor and 
0.1 to 0.5 p,g of EGFR kinase per tube.Assays were performed 
in the presence of increasing concentrations of balanol or tyr- 
phostin.The activity of Src kinase (10 ng per tube; gift of Dr 
Tony Hunter, Salk Institute, San Diego) was assayed essentially 
as described for the EGFR kinase but performed at 30 “C using 
heat-inactivated enolase (0.2 mg ml-l) as the phosphate accep- 
tor, with reactions terminated by spotting onto Whatman 3MM 
paper that was subsequently washed extensively with 10 % 
trichloroacetic acid/2.5 % pyrophosphate. The open circle in 
Figure 4b shows the effect of equivalent diluent (30 % DMSO) 
for the highest concentration of balanol used. 
Molecular modeling of balanol 
All the molecular modeling calculations were performed either 
on an SGI personal Iris 25G (energy minimizations and Monte 
Carlo methods) or on a Convex meta cluster C-240 (MOPAC 
calculations). An initial structural model for balanol was con- 
structed using the program Macromodel 3.1.This conformation 
was then subjected to energy minimization in the MM2 force 
field (500 steps using a conjugated gradient algorithm). The 
balarml conformer obtained by this method was then used as a 
starting structure for an extensive conformational search by 
Monte Carlo multiple-minimum calculations [30] using a gen- 
eralized Born solvent-accessible surface (GB/SA) model [22], in 
order to locate the global energy minimum. For this purpose a 
random scan search was performed, allowing all the flexible 
bonds to rotate in steps randomly chosen over the entire range 
of o-360”. The global minimum conformation that was 
obtained was further refined by ab initio calculations at the SCF 
level [31], using the Hamiltonian PM3 [32] contained in 
the program MOPAC (QCPE program # 455, available 
through the Quantum Chemical Program Exchange, QCPE, 
Department of Chemistry, Indiana University, Bloomington, IN 
47405). The structure for ATP was extracted from the ternary 
complex between cPKA, MnATP, and 5-24 PKI found in the 
Brookhaven database (structure name: latp). 
Comparison of the effects of balanol derivatives 
on PKC and PKA 
Balanol and its derivatives were added to reaction mixtures for 
either PKA or PKC.Assays were conducted as described above. 
Data are mean & SEM for two or three experiments except for 
balanol (n = 4). Curves were fitted by the program InStat 
(GraphPad Software, San Diego) using a single component 
competitive model. 
Determination of inhibition constants 
Ki values for balanol were estimated in two ways. For the inhi- 
bition of kinase activity in the presence varying concentrations 
ofATP (Figs 2e and 3c), K, values were determined using the 
dose-shift method of Cheng and Prusoff [33] in which p/L]-1 
= I/y, where L’ and L are the concentrations ofATP needed 
to generate half-maximal kinase activity in the presence or 
absence of balanol, I is the concentration of inhibitor (balanol, 
usually 10 nM) and K, is the apparent inhibition constant for 
the balanol-kinase interaction. All other K, values were calcu- 
lated from the concentration of inhibitor that produced 50 % 
inhibition of the enzyme activity [the IC,, value, generated by 
the program InPlot (GraphPad software)], with the assumption 
that all compounds compete for ATP as demonstrated for 
balanol and lo”-deoxybalanol. The apparent affinities of ATP 
for PKC (26 PM) or PKA (16 p,M) determined in replicates of 
the experiments shown in Figures 2e and 3c were used in the 
calculation. I$ = [IC,, x Kd] / [L + Kd], where IC,, is as above, 
Kd is the apparent affinity for ATP, and L is the concentration of 
ATP Data were derived using determinations from two to 
four experiments. 
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